Clinical and Pathologic Features Associated with Invasive Breast Carcinoma with 2018 ASCO/CAP Group ISH 2 Results (HER2/CEP17 ratio ≥2.0 and Average HER2 Copy Number of <4.0)

被引：0

作者：

Hoda, Raza ^{[1
]}

McIntire, Patrick ^{[1
]}

Komforti, Miglena ^{[1
]}

Downs-Kelly, Erinn ^{[1
]}

机构：

[1] Cleveland Clin, Cleveland, OH 44106 USA

来源：

MODERN PATHOLOGY | 2021年 / 34卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

100

引用

页码：111 / 113

页数：3

共 50 条

[21] Breast Cancers with HER2/CEP17 Ratio ≥2.0 and an Average HER2 Copy Number < 4.0 per Cell: Clinicopathologic Features and Alternative Chromosome 17 Probe Analysis of 102 Cases from a Single Institution Study
Bai, Qianming
Zhou, Shuling
Zhu, Xiaoli
Zhou, Xiaoyan
Yang, Wentao
MODERN PATHOLOGY, 2019, 32
[22] Breast Cancers with < 4 HER2 Signals/cell and Amplified HER2:CEP17 Ratios by FISH: Pathologic Features and Clinical Outcomes of Cases with "CEP17 Monosomy"
Ballard, Morgan
Troxell, Megan
Jensen, Kristin
Allison, Kimberly H.
LABORATORY INVESTIGATION, 2017, 97 : 31A - 31A
[23] Breast Cancers with < 4 HER2 Signals/cell and Amplified HER2:CEP17 Ratios by FISH: Pathologic Features and Clinical Outcomes of Cases with "CEP17 Monosomy"
Ballard, Morgan
Troxell, Megan
Jensen, Kristin
Allison, Kimberly H.
MODERN PATHOLOGY, 2017, 30 : 31A - 31A
[24] Prevalence of polysomy 17 by OncoScan in Fluorescence In Situ Hybridization (FISH) HER2 Gene amplification by HER2 gene copy number of > 6.0 with HER2/CEP17 ratio of < 2.0 in breast cancer
Apple, Sophia
Murata-Collins, Joyce
MODERN PATHOLOGY, 2018, 31 : 45 - 45
[25] Prevalence of polysomy 17 by OncoScan in Fluorescence In Situ Hybridization (FISH) HER2 Gene amplification by HER2 gene copy number of > 6.0 with HER2/CEP17 ratio of < 2.0 in breast cancer
Apple, Sophia
Murata-Collins, Joyce
LABORATORY INVESTIGATION, 2018, 98 : 45 - 45
[26] HER2 positive breast cancers with HER2:CEP17 ratio ≥2 and copy number >4 and <8 should require additional workup as recommended for Press groups G2-G4 in the 2018 ASCO/CAP HER2 update
Ericsson, Paula Gonzalez
Rexer, Brent
Wheeler, Ferrin
Yenamandra, Ashwini
Sanders, Melinda
MODERN PATHOLOGY, 2019, 32
[27] HER2 positive breast cancers with HER2: CEP17 ratio ≥2 and copy number > 4 and < 8 should require additional workup as recommended for Press groups G2-G4 in the 2018 ASCO/CAP HER2 update
Ericsson, Paula Gonzalez
Rexer, Brent
Wheeler, Ferrin
Yenamandra, Ashwini
Sanders, Melinda
LABORATORY INVESTIGATION, 2019, 99
[28] Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
Emad A. Rakha
Islam M. Miligy
Cecily M. Quinn
Elena Provenzano
Abeer M. Shaaban
Caterina Marchiò
Michael S. Toss
Grace Gallagy
Ciara Murray
Janice Walshe
Ayaka Katayama
Karim Eldib
Nahla Badr
Bruce Tanchel
Rebecca Millican-Slater
Colin Purdie
Dave Purnell
Sarah E. Pinder
Ian O. Ellis
Andrew H. S. Lee
British Journal of Cancer, 2021, 124 : 1836 - 1842
[29] Impact of Chromosome 17 and HER2 Copy Number Variability on HER2 FISH in Breast Cancer Cases with CEP17 Copy Number Alterations
Donaldson, Alana R.
Shetty, Shashirekha
Rivera, Christine
Portier, Bryce P.
Cook, James R.
Budd, G. T.
Downs-Kelly, Erinn
Klein, Roger D.
Lanigan, Christopher P.
Tubbs, Raymond
Calhoun, Benjamin C.
LABORATORY INVESTIGATION, 2016, 96 : 40A - 41A
[30] Impact of Chromosome 17 and HER2 Copy Number Variability on HER2 FISH in Breast Cancer Cases with CEP17 Copy Number Alterations
Donaldson, Alana R.
Shetty, Shashirekha
Rivera, Christine
Portier, Boyce P.
Cook, James R.
Budd, G. T.
Downs-Kelly, Erinn
Klein, Roger D.
Lanigan, Christopher P.
Tubbs, Raymond
Calhoun, Benjamin C.
MODERN PATHOLOGY, 2016, 29 : 40A - 41A

← 1 2 3 4 5 →

Clinical and Pathologic Features Associated with Invasive Breast Carcinoma with 2018 ASCO/CAP Group ISH 2 Results (HER2/CEP17 ratio ≥2.0 and Average HER2 Copy Number of &lt;4.0)

Clinical and Pathologic Features Associated with Invasive Breast Carcinoma with 2018 ASCO/CAP Group ISH 2 Results (HER2/CEP17 ratio ≥2.0 and Average HER2 Copy Number of <4.0)